Join the club for FREE to access the whole archive and other member benefits.

Yuri Deigin

Co-founder and Director at YouthBio Therapeutics

Yuri is a biotech entrepreneur with a focus on early-stage translation of scientific breakthroughs into therapies. He has over a decade of drug discovery and development experience, and a track record of outlicensing products to Big Pharma.

Yuri has previously led several early-stage pharmaceutical startups, including one developing an Alzheimer's Disease therapeutic, and another startup developing small-molecule neuroprotectors for Alzheimer's, Parkinson's, and a rare pediatric disease.

Additionally, Yuri has been a vocal evangelist of epigenetic rejuvenation by partial reprogramming with Yamanaka factors since 2017.

Visit website: https://youthbiotx.com/#yuri

 yurideigin

 ydeigin

See also: Company YouthBio Therapeutics - Developing rejuvenation gene therapies based on partial reprogramming by Yamanaka factors

Details last updated 02-Apr-2022

Yuri Deigin is also referenced in the following:

Longevity Summit Dublin 2023

17-Aug-2023 to 20-Aug-2023
Club discount available - click here

Event gathering Global Longevity and Rejuvenation community in Dublin with many longevity movement superstars as speakers

YouthBio Therapeutics

Developing rejuvenation gene therapies based on partial reprogramming by Yamanaka factors

Yuri Deigin | Epigenetic Reprogramming, Cryonics & COVID Lab Leak

Live Longer World podcast #17 with Yuri Deigin as a guest

Yuri Deigin News

Unveiling the future of age reversal: meet Yuri Deigin, founder of YouthBio Therapeutics

Longevity Technology - 08-Mar-2023

Tissue-specific gene therapies & rejuvenating factors to extend lifespan and combat age-related diseases

Read more...

Reason reports back from October's Rejuvenation Startup Summit

Fight Aging! - 19-Oct-2022

Some really exciting developments with quite a few in clinical trials

Read more...

YouthBio Therapeutics unveils its board, with João Pedro de Magalhães as CSO

CISION PR Newswire - 14-Apr-2022

Another company enters the cellular reprogramming race - hopefully at least one will cross the finishing line

Read more...